XML 40 R27.htm IDEA: XBRL DOCUMENT v3.26.1
Other Revenue (Tables)
 3 Months Ended
Mar. 31, 2026
Revenue Recognition and Deferred Revenue [Abstract]  
Schedule of Disaggregation of Revenue
Net product sales by product type were as follows (in millions):
Three Months Ended March 31,
20262025
COVID(1)
$345 $84 
RSV
7 2 
Total $352 $86 
_______
(1)Includes sales of Spikevax and mNEXSPIKE.
The following table summarizes product sales provision adjustments for the periods presented (in millions):
Three Months Ended March 31,
20262025
Gross product sales $350 $105 
Product sales provision:
Wholesaler chargebacks, discounts and fees
11 (22)
Returns, rebates and other fees
(9)3 
Total product sales provision adjustments
$2 $(19)
Net product sales $352 $86 
The following table summarizes other revenue for the periods presented (in millions):
Three Months Ended March 31,
20262025
Stand-ready manufacturing revenue
$32 $12 
Collaboration revenue (Note 5)
5 1 
Grant revenue— 1 
Licensing and royalty revenue
— 8 
Total other revenue$37 $22